BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28345779)

  • 1. Sacral neuromodulation for detrusor hyperactivity with impaired contractility.
    Hennessey DB; Hoag N; Gani J
    Neurourol Urodyn; 2017 Nov; 36(8):2117-2122. PubMed ID: 28345779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sacral Neuromodulation by Converting Constant Frequency Stimulation Into Variable Frequency Stimulation in Patients With Detrusor Overactivity and Impaired Contractility: A Single-Center Prospective Study.
    Zhu W; Shan S; Zhang G; Zhang Q; Zhang J; Che Y; Wen J; Wang Q
    Neuromodulation; 2023 Dec; 26(8):1836-1844. PubMed ID: 35977853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mirabegron, a β
    Lee CL; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O93-O97. PubMed ID: 29697209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.
    Wang CC; Lee CL; Kuo HC
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
    Marinkovic SP; Ford JC
    BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pre-operative bladder contractility as a predictor of improved response rate to a staged trial of sacral neuromodulation in patients with detrusor underactivity.
    Chan G; Qu LG; Gani J
    World J Urol; 2021 Jun; 39(6):2113-2119. PubMed ID: 32725304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
    Timm B; Jayarajan J; Chan G; Bolton D
    Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the efficacy of a new variable frequency stimulation sacral neuromodulation in the treatment of detrusor hyperactivity with impaired contractility].
    Zhu W; Shan SS; Zhang QY; Zhang J; Zhang CY; Wang CY; Jia ZM; Zhang GX; Wang Y; Che YY; Wen JG; Wang QW
    Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(2):147-151. PubMed ID: 35012305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differences of urodynamic tests between patients of detrusor hyperactivity with impaired contractility with and without bladder outlet obstruction and effect of anticholinergic medications in these patients].
    Liu N; He F; Man LB; Huang GL; Wang HD; Wang H; Li GZ; Wang JW
    Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(26):1824-7. PubMed ID: 22944232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed Investigation of Bladder Diary Parameters During Sacral Neuromodulation in Patients With Overactive Symptoms.
    Van de Borne S; Tilborghs S; Vaganée D; Vermandel A; De Wachter S
    Neuromodulation; 2023 Dec; 26(8):1831-1835. PubMed ID: 36266179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of opioid receptors in inhibition of bladder overactivity induced by sacral neuromodulation in pigs: A possible action mechanism.
    Li X; Liao L; Chen G; Wang Z; Deng H
    Neurourol Urodyn; 2017 Sep; 36(7):1742-1748. PubMed ID: 27935110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urodynamic characteristics of detrusor underactivity in women with voiding dysfunction.
    Yang TH; Chuang FC; Kuo HC
    PLoS One; 2018; 13(6):e0198764. PubMed ID: 29924821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical and Urodynamic Results of Percutaneous Posterior Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Patients With Parkinson's Disease.
    Kabay S; Canbaz Kabay S; Cetiner M; Mestan E; Sevim M; Ayas S; Ozden H; Ozisik Karaman H
    Urology; 2016 Jan; 87():76-81. PubMed ID: 26436213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
    Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study.
    Jairam R; Drossaerts J; Vrijens D; Leue C; van Kerrebroeck P; van Koeveringe G
    Neurourol Urodyn; 2018 Jun; 37(5):1801-1808. PubMed ID: 29504634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.